REST THERAPEUTICS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
Phase 1
Withdrawn
- Conditions
- Alzheimer DiseaseTreatment Resistant DepressionPTSDMajor Depressive DisorderNeuro-Degenerative DiseaseBrain Diseases
- Interventions
- Drug: Fluoroethylnormemantine (FENM)
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- ReST Therapeutics
- Registration Number
- NCT05921929
- Locations
- 🇧🇪
CHU of Liège - Clinical Pharmacology Unit, Liège, Belgium
© Copyright 2025. All Rights Reserved by MedPath